Literature-reported formulation composition
Component: GVS-18-B6 | mol%: 54.6 | Role: Ionizable lipid
sales@dcchemicals.com
Lipid GVS-18-B6
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: DSPC | mol%: 10.9 | Role: Helper phospholipid
Literature-reported formulation composition
Component: Cholesterol | mol%: 32.8 | Role: Sterol
Literature-reported formulation composition
Component: PEG-conjugated lipid (identity not specified in article) | mol%: 1.6 | Role: PEG lipid
Literature-reported formulation composition
Component: Reported total | mol%: 99.9 | Role: Source values retained
Reported observation
Literature-reported Z-average particle size 89 nm Post-formulation characterization Table 1, p. 10376
Reported observation
Literature-reported Polydispersity index 0.06 Post-formulation characterization Table 1, p. 10376
Reported observation
Literature-reported mRNA encapsulation efficiency 90% Post-formulation characterization Table 1, p. 10376
Reported observation
Literature-reported Apparent LNP pKa 6.15 TNS binding assay Table 1, p. 10376; TNS method, p. 10382
Reported observation
Literature-reported Zeta potential at pH 5.5 +2.69 mV Post-formulation characterization Table 1, p. 10376
Reported observation
Literature-reported Zeta potential at pH 7.5 +0.98 mV Post-formulation characterization Table 1, p. 10376
Reported observation
Literature-reported Liver EGFP expression 5.30 × 10^7 pg EGFP/g liver 24 h after IV administration · 2.56-fold the MC3 value in the same table Table 1, p. 10376
Reported observation
Literature-reported Spleen EGFP expression 0.58 × 10^6 pg EGFP/g spleen 24 h after IV administration Table 1, p. 10376
Reported observation
Calculated from literature Liver-to-spleen EGFP ratio Approximately 92:1 24 h after IV administration · Benchmarks reported at approximately 10:1 to 20:1 Calculated from Table 1 values; ratio also stated in text, p. 10377
Reported observation
Literature-reported Plasma MCP-1 81 pg/mL 6 h after IV administration · MC3: 159 pg/mL in the same table Table 1 and Figure 2 caption, p. 10376
Reported observation
Rapid mouse liver clearance The parent GVS-18-B6 lipid was reported as almost completely cleared from mouse liver within 6 hours after IV dosing. EGFP mRNA LNP; IV; mouse; LC-MS · Figure 2 and text, pp. 10376-10377
Reported observation
Mouse tolerability GVS-18-B6 LNPs were reported as well tolerated at doses up to 6 mg/kg, with little elevation in the measured ALT, AST, MCP-1 or IL-6 biomarkers. Nonstimulatory siRNA LNP; IV; female BALB/c mice · Figure 3 and text, pp. 10377-10378
Reported observation
NHP single-dose expression and clearance After a 1 mg/kg IV infusion of hOTC mRNA LNP, strong hOTC expression was reported in liver, with substantially lower expression in spleen; the vast majority of GVS-18-B6 was degraded in liver within 24 hours. hOTC mRNA LNP; 1 mg/kg; 60-minute IV infusion; cynomolgus monkeys · Figure 5A-C and text, pp. 10378-10379
Reported observation
NHP repeat dosing Weekly 0.25 mg/kg IV doses for five weeks produced comparable plasma hEPO profiles after doses 1 and 5, with no efficacy pattern indicative of accelerated blood clearance in the reported experiment. hEPO mRNA LNP; 0.25 mg/kg; IV every 7 days × 5; cynomolgus monkeys · Figure 5D and text, pp. 10378-10379